Brokerages Set Sensus Healthcare, Inc. (NASDAQ:SRTS) Price Target at $5.05

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have earned an average recommendation of “Buy” from the seven analysts that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $5.05.

A number of research analysts have issued reports on the company. Roth Capital boosted their price target on Sensus Healthcare from $4.00 to $6.00 and gave the stock a “buy” rating in a research report on Thursday, March 4th. HC Wainwright boosted their price target on Sensus Healthcare from $4.00 to $6.00 and gave the stock a “buy” rating in a research report on Monday, March 8th. Northland Securities upgraded Sensus Healthcare from a “market perform” rating to an “outperform” rating in a research report on Friday, February 26th. Finally, Zacks Investment Research upgraded Sensus Healthcare from a “sell” rating to a “hold” rating in a research report on Wednesday, March 3rd.

NASDAQ:SRTS traded up $0.03 during midday trading on Friday, reaching $3.85. 14,002 shares of the company traded hands, compared to its average volume of 478,475. Sensus Healthcare has a twelve month low of $1.76 and a twelve month high of $6.09. The firm has a market capitalization of $63.47 million, a price-to-earnings ratio of -9.17 and a beta of 0.49. The company has a fifty day moving average price of $4.19 and a 200 day moving average price of $3.52.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings results on Thursday, February 25th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.18. Sensus Healthcare had a negative return on equity of 28.68% and a negative net margin of 52.46%. On average, sell-side analysts predict that Sensus Healthcare will post -0.6 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Invenomic Capital Management LP raised its stake in shares of Sensus Healthcare by 39.6% in the 4th quarter. Invenomic Capital Management LP now owns 303,766 shares of the company’s stock worth $1,172,000 after buying an additional 86,139 shares in the last quarter. BlackRock Inc. raised its stake in shares of Sensus Healthcare by 2.4% in the 4th quarter. BlackRock Inc. now owns 113,689 shares of the company’s stock worth $439,000 after buying an additional 2,661 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Sensus Healthcare by 9.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 46,283 shares of the company’s stock worth $179,000 after buying an additional 4,163 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Sensus Healthcare by 45.9% in the 4th quarter. Renaissance Technologies LLC now owns 18,434 shares of the company’s stock worth $71,000 after buying an additional 5,800 shares in the last quarter. 7.69% of the stock is currently owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Further Reading: Is a Roth IRA right for you?